SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

(Amendment 1vo. 2)			
Praxis Precision Medicines, Inc.			
(Name of Issuer)			
Common Stock, par value \$0.0001 per share			
(Title of Class of Securities)			
74006W207			
(CUSIP Number)			
September 30, 2024			
(Date of Event Which Requires Filing of this Statement)			
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:			
and appropriate control aconginate the rand parounds to which this sentence is inten-			
☐ Rule 13d-1(b)			
■ Rule 13d-1(c)			
☐ Rule 13d-1(d)			
(Page 1 of 11 Pages)			
(1 mgc 1 01 11 1 mgco)			

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1	NAME OF REPORTING PERSON			
	Point72 Asset Management, L.P.			
2	CHECK THE A	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) (b)		
3	SEC USE ONLY	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	5	SOLE VOTING POWER 0		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)		
	7	SOLE DISPOSITIVE POWER 0		
	8	SHARED DISPOSITIVE POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)			
10	CHECK BOX II	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%			
12	TYPE OF REPO	DRTING PERSON		

	NAME OF DE	DODTRIC DEDGOVI			
1	NAME OF RE	NAME OF REPORTING PERSON			
	Point72 Capital Advisors, Inc.				
2	CHECK THE	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)			
_	(a) □ (b) 図				
3	SEC USE ONI	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware				
	5	SOLE VOTING POWER 0			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)			
	7	SOLE DISPOSITIVE POWER 0			
	8	SHARED DISPOSITIVE POWER 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,694,274 shares of Common Stock (including 150,000 shares of Common stock issuable upon exercise of options and 511,030 shares of Common Stock issuable upon exercise of warrants)				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%				
12	TYPE OF REF	ORTING PERSON			

1	NAME OF REPORTING PERSON			
	Point72 Biotech Private Investments, LLC			
2	CHECK THE AF	(a) [] (b) 🗵		
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	5	SOLE VOTING POWER 0		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 65,933		
	7	SOLE DISPOSITIVE POWER 0		
	8	SHARED DISPOSITIVE POWER 65,933		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,933			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%			
12	TYPE OF REPORTING PERSON OO			

1	NAME OF RE	NAME OF REPORTING PERSON			
_					
	Differen	Differentiated Ventures Investments, LLC			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
_			(a) ∐ (b) ⊠		
3	SEC USE ONI	SEC USE ONLY			
	CITIZENSUID	CITIZENSHIP OR PLACE OF ORGANIZATION			
4	Delawar				
	5	SOLE VOTING POWER 0			
NUMBER OF		U U			
SHARES	6	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		65,933			
EACH	7	SOLE DISPOSITIVE POWER			
REPORTING	,	0			
PERSON WITH	8	SHARED DISPOSITIVE POWER			
	0	65,933			
0	AGGREGATE	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9	65,933				
10	CHECK BOX	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	PERCENT OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11	0.4%				
	TYPE OF PER				
12	TYPE OF REPORTING PERSON OO				

1	NAME OF REPORTING PERSON			
	72 Investment Holdings, LLC			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	5	SOLE VOTING POWER 0		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 65,933		
	7	SOLE DISPOSITIVE POWER 0		
	8	SHARED DISPOSITIVE POWER 65,933		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,933			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%			
12	TYPE OF REPORTING PERSON OO			

1	NAME OF REPORTING PERSON			
_	Stavan A. Cohan			
	Steven A. Cohen			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)			
			(b) X	
3	SEC USE ON	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	United	States		
	5	SOLE VOTING POWER		
		0		
NUMBER OF	6	SHARED VOTING POWER		
SHARES		1,760,207 shares of Common Stock (including 150,000 shares of Common upon exercise of options and 511,030 shares of Common Stock issuable to the common Stock is subject to the common sto		
BENEFICIALLY OWNED BY		warrants)		
EACH	7	SOLE DISPOSITIVE POWER		
REPORTING PERSON WITH	/	0		
	8	SHARED DISPOSITIVE POWER		
		1,760,207 (including 150,000 shares of Common stock issuable upon exe 511,030 shares of Common Stock issuable upon exercise of warrants)	ercise of options and	
9		E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON OF shares of Common Stock (including 150,000 shares of Common stock issuable)	a unon evergise of	
		and 511,030 shares of Common Stock issuable upon exercise of warrants)	c upon exercise of	
10	CHECK BOX	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
10			Ц	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	9.6%			
12	_	PORTING PERSON		
	IN			

Item 1(a). Name of Issuer.

Praxis Precision Medicines, Inc. (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices.

99 High Street, 30th Floor, Boston, MA 02110.

Item 2(a). Name of Person Filing.

This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to shares of common stock, par value \$0.0001 per share ("Common Stock"), of the Issuer held by (and shares of Common Stock underlying the warrants and options held by) Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to shares of Common Stock held by (and shares of Common Stock underlying the warrants and options held by) Point72 Associates; (iii) Point72 Biotech Private Investments, LLC ("Point72 Biotech") with respect to shares of Common Stock of which it is the holder; (iv) Differentiated Ventures Investments, LLC ("Differentiated Ventures"), the managing member of Point72 Biotech, with respect to the shares of Common Stock held by Point72 Biotech; (v) 72 Investment Holdings, LLC ("72 Investment Holdings"), the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by Point72 Biotech, and (vi) Steven A. Cohen ("Mr. Cohen") with respect to shares of Common Stock beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings.

Item 2(b). Address of Principal Business Office.

The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

Item 2(c). Place of Organization.

Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Point72 Biotech, Differentiated Ventures, and 72 Investment Holdings are Delaware limited liability companies. Mr. Cohen is a United States citizen.

Item 2(d). Title of Class of Securities.

Common Stock, par value \$0.0001 per share.

Item 2(e). CUSIP Number.

74006W207

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is

a:

Not applicable.

Item 4. Ownership.

The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024.

Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to securities held by Point72 Associates. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.

Differentiated Ventures is the managing member of Point72 Biotech and may be deemed to share beneficial ownership over the shares of Common Stock held by Point72 Biotech. 72 Investment Holdings is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner.

The filing of this statement should not be construed as an admission that any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

The aggregate percentage of the Common Stock reported to be beneficially owned by each Reporting Person is based on 18,268,099 shares of Common Stock outstanding which is the sum of: (i) 17,757,069 shares of Common Stock outstanding as of August 9, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024; and (ii) 511,030 warrant shares exercised as reported herein.

Ownership of Five Percent or Less of a Class. Item 5.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Item 7. Parent Holding Company or Control Person. Not applicable.

Identification and Classification of Members of the Group. Item 8.

Not applicable.

Item 9. **Notice of Dissolution of Group.**

Not applicable.

Item 10. Certification.

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024

POINT72 ASSET MANAGEMENT, L.P.

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

POINT72 CAPITAL ADVISORS, INC.

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

POINT72 BIOTECH PRIVATE INVESTMENTS, LLC

By: /s/ Vincent Tortorella
Name: Vincent Tortorella
Title: Authorized Person

DIFFERENTIATED VENTURES INVESTMENTS, LLC

By: /s/ Vincent Tortorella
Name: Vincent Tortorella
Title: Authorized Person

72 INVESTMENT HOLDINGS, LLC

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

STEVEN A. COHEN

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person